MedPath

Efficacy and Safety of Minocycline or Tetracycline Combined with Vonoprazan as a Dual Therapy for First-line Treatment of Helicobacter pylori Infection

Phase 1
Conditions
Helicobacter pylori infection
Registration Number
ChiCTR2400088709
Lead Sponsor
Peking University First Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Age between 18 and 80 years, no gender restriction;<br>2. Positive for Helicobacter pylori (indicated by a positive urease breath test and determined by a doctor to require treatment for Helicobacter pylori infection);<br>3. Allergic to penicillin (including those with a positive penicillin skin test or who have experienced an allergic reaction after using penicillin).
Exclusion Criteria
  1. Patients who have previously undergone treatment for Helicobacter pylori;<br>2. Pregnant or breastfeeding women;<br>3. Those who have used antibiotics, bismuth agents, or acid suppressants (PPI or P-cab) within 4 weeks prior to treatment;<br>4. Patients with other serious diseases that could affect the evaluation of this study, such as severe liver disease, heart disease, kidney disease, malignant tumors, or alcoholism;<br>5. Individuals allergic to the drugs used in this study (vonoprazan fumarate, tetracycline, minocycline) or their components, or who need to use these drugs with caution or are contraindicated due to underlying diseases or concurrent medications;<br>6. Participants in other drug studies within 3 months prior to using the study drug;<br>7. Patients who are unable to properly express their complaints, such as those with psychiatric disorders or severe neurosis, and are unable to cooperate with the trial;<br>8. Other situations that the researcher deems unsuitable for participation in this trial.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eradication rate;
Secondary Outcome Measures
NameTimeMethod
Safety;Side effects;adherence;
© Copyright 2025. All Rights Reserved by MedPath